With SGLT2 inhibitors now joining the mainstream of therapies for heart failure, it’s time to look at other novel approaches such as intravenous iron, vericiguat and omecamtiv mercarbil, according to an international expert. Speaking at CSANZ 2020 virtual meeting, Professor John Teerlink of the University of California, San Francisco, said much could still be achieved ...
3 novel therapies for heart failure – Prof John Teerlink
By Michael Woodhead
15 Dec 2020